Mitochondria targeted hydrogen sulfide donor AP39 attenuates allergic airway inflammation and airway hyperreactivity in mouse
Respiratory Physiology & Neurobiology · 2026
DOI: 10.1016/j.resp.2025.104501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiratory Physiology & Neurobiology, 2026. Verfasst von Bartu Altiparmak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey; Section of Cardiology, Department of Medicine, University of C…. Hauptthemen laut MEDLINE: Asthma, Mitochondria, Bronchial Hyperreactivity, Hydrogen Sulfide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Hacettepe University.
Abstract (Originalsprache)
BACKGROUND: Asthma is a multifactorial chronic inflammatory airway disease affecting 5 % of children and 10 % of adults and there is no curative treatment. Recent studies have revealed that mitochondrial dysfunction is an important contributor to the pathophysiology of various respiratory diseases. OBJECTIVES: In this study, the effect of AP39, a mitochondria-targeted slow-releasing hydrogen sulfide (H2S) donor, was investigated in a mouse model of ovalbumin (OVA)-induced allergic asthma. METHODS: Pulmonary function (airway resistance and dynamic compliance), inflammatory cells and cytokines in bronchoalveolar lavage (BAL) fluid, and histopathology of the lungs were evaluated in 8-12-week-old female C57BL/6 mice. RESULTS: The OVA-induced allergic asthma model resulted in bronchial hyperreactivity, inflammatory cell infiltration in peribronchial and parenchymal areas in the lungs, increased Th2 cytokines and eosinophil numbers in BAL fluid. Treatment with AP39 (1000 nmol/kg) prevented bronchial hyperreactivity and suppressed the elevated IL-4, IL-5 and IL-13 cytokine levels, inhibited the increase of lymphocyte and eosinophil cells, and reduced histopathological changes in lung tissue. Treatment with a lower dose of AP39 (250 nmol/kg) had slightly less but still significant effects on bronchial hyperreactivity, inflammatory cells and histopathological changes, yet had no effect on cytokine levels. CONCLUSION: AP39 treatment prevented pathophysiological changes in allergic airway inflammation. Therefore, targeting the mitochondria with H2S donors may be a promising therapeutic potential in allergic respiratory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey; Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA. Electronic address: bartualtiparmak@hacettep…
- Department of Pharmacology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
- Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Förderung
- Hacettepe University
Zitieren
APA
Altiparmak, B., Karaman, Y., Kurtulan, O., Onder, S. C., & Bozkurt, T. E. (2026). Mitochondria targeted hydrogen sulfide donor AP39 attenuates allergic airway inflammation and airway hyperreactivity in mouse. Respiratory Physiology & Neurobiology. https://doi.org/10.1016/j.resp.2025.104501
Vancouver
Altiparmak B, Karaman Y, Kurtulan O, Onder SC, Bozkurt TE. Mitochondria targeted hydrogen sulfide donor AP39 attenuates allergic airway inflammation and airway hyperreactivity in mouse. Respiratory Physiology & Neurobiology. 2026. doi:10.1016/j.resp.2025.104501
BibTeX
@article{Altiparmak2026,
author = {Altiparmak, Bartu and Karaman, Yasemin and Kurtulan, Olcay and Onder, Sevgen Celik and Bozkurt, Turgut Emrah},
title = {Mitochondria targeted hydrogen sulfide donor AP39 attenuates allergic airway inflammation and airway hyperreactivity in mouse},
journal = {Respiratory Physiology & Neurobiology},
year = {2026},
doi = {10.1016/j.resp.2025.104501}
}
EUVIMED